Achieve Life Sciences Q3 net loss widens
Achieve Life Sciences reported a widened net loss for Q3, missing analyst expectations with an EPS of -$0.28 against a consensus of -$0.26. The company’s net loss was $14.44 million, exceeding the expected $12.20 million. The FDA accepted the NDA for cytisinicline, with a PDUFA date set for June 20, 2026. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $13.00, reflecting a potential upside of 62.1% from its recent closing price of $4.93.
)
Overview
- Achieve Q3 net loss and EPS missed analyst expectations
- FDA accepted NDA for cytisinicline in smoking cessation, PDUFA date set for June 2026
- Awarded FDA Commissioner’s National Priority Voucher for vaping cessation
Outlook
- Company confirms PDUFA action date for cytisinicline as June 20, 2026
- Achieve awarded FDA Priority Voucher for vaping cessation
- Company highlights unmet need in vaping cessation market
Result Drivers
- Total operating expenses for the three and nine months ended September 30, 2025, were $14.7 million and $40.1 million, respectively
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 EPS Miss -$0.28 -$0.26
(7
Analysts
)
Q3 Net Miss -$14.44 -$12.20
Income mln mln (7
Analysts
)
Q3 Miss -$14.69 -$12.10
Income mln mln (7
From Analysts
Operatio )
ns
Q3 $14.69
Operatin mln
g
Expenses
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 7 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Achieve Life Sciences Inc is $13.00, about 62.1% above its November 5 closing price of $4.93
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
